Summary
We have studied the kinetics of a single oral dose of mefloquine (750 mg) in 12 Thai patients with falciparum malaria and have compared the results with those of a previous study in 12 healthy Thai volunteers [6].
All the patients responded to treatment with a mean parasite clearance time of 66.6 h and a mean fever clearance time of 54.1 h.
There was no significant difference in peak plasma concentration, time to peak, area under the curve or apparent volume of distribution between patients and controls. However, the terminal half-life (t1/2) and mean residence time (MRT) were shorter in the patients (12.2 vs 16.7 days for t1/2 and 15.5 vs 21.4 days for MRT).
We conclude that there are changes in the disposition of mefloquine related to malaria, although the exact basis of the changes is not clear.
This is a preview of subscription content, log in via an institution to check access.
References
Harinasuta T, Bunnag D, Wernsdorfer WH (1983) A phase II clinical trial of mefloquine in patients with chloroquine resistant falciparum malaria in Thailand. Bull WHO 61: 299–305
De Souza JM (1983a) A phase I clinical trial of mefloquine in Brazilian male subjects. Bull WHO 61: 809–814
De Souza JM (1983b) A phase II clinical trial of mefloquine in Brazilian male subjects. Bull WHO 61: 815–820
De Souza JM, Sheth UK, De Oliveira RMG, Roulet LH, De Souza SD (1985) An open randomized phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil. Bull WHO 63: 603–609
Looareesuwan S, White NJ, Warrell DA, Forgo I, Dubach UG, Ranalder UB, Schwartz DE (1987) Studies of mefloquine bioavailability and kinetics using a stable isotope technique: A comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. Br J Clin Pharmacol 24: 37–42
Karbwang J, Bunnag D, Breckenridge AM, Back DJ (1987) The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. Eur J Clin Pharmacol 32: 173–177
Riviere JH, Back DJ, Breckenridge AM, Howells RE (1985) The pharmacokinetics of mefloquine in man. Lack of effect of mefloquine on antipyrine metabolism. Br J Clin Pharmacol 20: 469–474
Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
Schwartz DE, Eckert G, Hartmann D, Weber D, Richard-Lenoble D, Ekue JMK, Gentilini M (1982) Single dose kinetics of mefloquine in man. Chemotherapy 28: 70–84
Mu JY, Israili ZH, Dayton PG (1975) Studies of the disposition and metabolism of mefloquine HCl (WR 142, 490) a quinolinemethanol antimalarial in the rat. Drug Metab Dispos 3: 198–210
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karbwang, J., Back, D.J., Bunnag, D. et al. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur J Clin Pharmacol 35, 677–680 (1988). https://doi.org/10.1007/BF00637607
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637607